No Data
shen zhen weiguang biological products (002880.SZ): Director and Chief Financial Officer Yue Zhangbiao resigns.
Gelonghui November 29th 丨 Shen Zhen Weiguang Biological Products (002880.SZ) announced that the board of directors of the company recently received a resignation report from Mr. Yue Zhangbiao, director and CFO of the company. Due to personal reasons, Mr. Yue Zhangbiao resigned from the positions of director and CFO of the company to the board of directors, and will no longer hold any position in the company after resigning.
Express News | Shen Zhen Weiguang Biological Products: Signed a strategic cooperation agreement with Shenzhen Polytechnic University.
Shen Zhen Weiguang Biological Products (002880): Rapid income growth with cost rate reduction leading to profit release.
Event: The company released the third quarter report for 2024, with revenue of 0.85 billion yuan in the first three quarters of 2024, a year-on-year increase of +16.1%, net income attributable to parent company of 0.18 billion yuan, a year-on-year increase of +20.8%, and non-net income attributable to parent company of 0.18 billion yuan, a year-on-year increase of
shen zhen weiguang biological products (002880): The continuous enrichment of product approvals demonstrates the confidence in the employee stock ownership plan.
Event: On October 26, 2024, the company released the third-quarter report of 2024: the company's revenue for the first three quarters of 2024 was 0.854 billion yuan ( year-on-year +16.14% ), net income attributable to the parent 1.
shen zhen weiguang biological products (002880): Q3 profit growth rate bright, China National Pharmaceutical Group's acquisition is expected to further empower.
On October 25, 2024, shen zhen weiguang biological products released the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.854 billion, up 16.14% year-on-year, and achieved a net income attributable to the parent of 1.83.
Weiguang Biotech: Report for the third quarter of 2024
